Cargando…
Immunovirotherapy Based on Recombinant Vesicular Stomatitis Virus: Where Are We?
Vesicular stomatitis virus (VSV), a negative-strand RNA virus of the Vesiculovirus genus, has demonstrated encouraging anti-neoplastic activity across multiple human cancer types. VSV is particularly attractive as an oncolytic agent because of its broad tropism, fast replication kinetics, and amenab...
Autores principales: | Zhang, Yuguo, Nagalo, Bolni Marius |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273848/ https://www.ncbi.nlm.nih.gov/pubmed/35837384 http://dx.doi.org/10.3389/fimmu.2022.898631 |
Ejemplares similares
-
Oncolytic Virus with Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers
por: Nagalo, Bolni Marius, et al.
Publicado: (2020) -
Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses
por: Jafari, Mahdie, et al.
Publicado: (2022) -
Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector
por: Clarke, David K., et al.
Publicado: (2006) -
Immunological correlates of protection afforded by PHV02 live, attenuated recombinant vesicular stomatitis virus vector vaccine against Nipah virus disease
por: Monath, Thomas P., et al.
Publicado: (2023) -
Immunovirotherapy for glioblastoma
por: Ning, Jianfang, et al.
Publicado: (2014)